Topic summary

Journal club: is percentage weight change the right endpoint?

Evidence › Journal club number needed to treat randomised trial journal club Solved

This is a generated summary. It shows the 9 most-liked posts from a topic of 121, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.

b.wikstromTL2 Moderator Solution22 Mar 2026#8

f.lindholm, post #2: Critical appraisal template: (1) What did the trial set out to estimate? (2) Could the design answer that question? (3) Was the population sufficiently similar to your population to apply the results? (4) What was the absolute effect, not just the relative one? (5) What are the two strongest criticisms available? Go to post

SURMOUNT-1 (N Engl J Med 2022): Tirzepatide obesity trial. The largest mean weight reduction for a pharmacological intervention at publication. Read the categorical thresholds carefully — they can exaggerate separation.

25 likes in reply to #2 4mo

KnowltonTL3Regular29 Mar 2026#22

post #21 answers the question as asked. The question underneath it is different.

SURPASS-2 (N Engl J Med 2021): Direct comparison of tirzepatide with semaglutide 1.0 mg. The 1.0 mg dose is not the highest available, which is the central and legitimate criticism of the head-to-head evidence.

29 likes 4mo

VThorvaldsenTL3Regular31 Mar 2026#28

FLOW (N Engl J Med 2024): Semaglutide renal outcomes in type 2 diabetes and chronic kidney disease. Stopped early for efficacy. Component-by-component analysis is essential because the components differ in how patient-important they are.

28 likes 4mo

excursion_checkTL3Regular1 Apr 2026#31

Picking up post #28: that is the part I would want checked first.

32 likes 4mo

a.weissTL2 Moderator15 Apr 2026#70

t.abubakar, post #36: I read post #34 twice before replying, because I had assumed the opposite. Session format: read the paper before posting. The discussion is much better when everyone has. Start with the estimand and population, then methods, then results, then limitations. That order makes critique coherent. Go to post

post #69 is right about the mechanism and I think understates the practical bit.

28 likes in reply to #36 3mo

GDashwoodTL3Regular18 Apr 2026#79

This follows post #76 rather than contradicting it.

For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add the caveats that make it safe to use.

30 likes in reply to #36 3mo

n.vogelTL2 Moderator22 Apr 2026#91

For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add the caveats that make it safe to use.

31 likes 3mo

s.ferreiraTL2 Moderator23 Apr 2026#97

excursion_check, post #31: Picking up post #28: that is the part I would want checked first. SURPASS-2 (N Engl J Med 2021): Direct comparison of tirzepatide with semaglutide 1.0 mg. The 1.0 mg dose is not the highest available, which is the central and legitimate criticism of the head-to-head evidence. Go to post

Picking up post #94: that is the part I would want checked first.

29 likes in reply to #31 3mo

c.nybergTL2 Moderator27 Apr 2026#109

29 likes 3mo

Read the full topic (121 posts)

This topic was referenced in

Journal club: orforglipron phase 2 and the non-peptide questionEvidence › Journal club · 132 replies

Suggested topics

Topic	Participants	Replies	Views	Activity
Journal club: SUSTAIN 6 and its retinopathy signal Evidence › Journal club estimand effect size risk of bias journal club Under review On the subject in the title: Journal club: SUSTAIN 6 and its retinopathy signal Working notes rather than a conclusion. I have seen SELECT ( N Engl J Med , 2023) cited in support of a claim I do not think it…	+110	122	46k	1d
Journal club: how we handle discontinuation in obesity trials — what changed since Evidence › Journal club number needed to treat estimand risk of bias randomised trial Solved Journal club: how we handle discontinuation in obesity trials — what changed since — setting out what I have, and where I think it stops being reliable. Session topic: STEP 4 ( JAMA , 2021). Please read it…	+14	18	35k	8mo
Follow-up: Journal club: the retatrutide phase 2 obesity paper Evidence › Journal club randomised trial risk of bias effect size journal club Closed On the subject in the title: Journal club: the retatrutide phase 2 obesity paper Working notes rather than a conclusion. I have seen SURMOUNT-1 ( N Engl J Med , 2022) cited in support of a claim I do not…	+20	24	8.7k	16mo
Revisiting: Journal club: SURMOUNT-OSA and a hard endpoint in a soft field Evidence › Journal club estimand risk of bias number needed to treat Revisiting: Journal club: SURMOUNT-OSA and a hard endpoint in a soft field — setting out what I have, and where I think it stops being reliable. Comparing LEADER ( N Engl J Med , 2016) with SUSTAIN 6 ( N Engl…	+108	122	52k	7d
Journal club: SELECT, absolute risk, and how it was reported Evidence › Journal club journal club estimand randomised trial effect size Journal club: SELECT, absolute risk, and how it was reported Writing it up because I had to work it out twice and would rather nobody else did. Session topic: SURMOUNT-OSA ( N Engl J Med , 2024). Please read…		2	52k	1mo

Related topics — sharing the tags number needed to treat, randomised trial, journal club

Topic	Participants	Replies	Views	Activity
Is "synergy" the right word for the combination data? Compounds › Cagrilintide & amylin analogues randomised trial cagrilintide effect size Is "synergy" the right word for the combination data? — that is the question, and I have not found it answered plainly anywhere I have looked. Session topic: SCALE ( N Engl J Med , 2015). Please read it…	+5	9	13k	25d
[2026 update] What the GIP component of tirzepatide is thought to contribute, and how confident we can be Compounds › Tirzepatide SURPASS programme randomised trial effect size Under review The question in the title: What the GIP component of tirzepatide is thought to contribute, and how confident we can be I will give what I have already checked below so nobody repeats it. Comparing STEP 4 (…	+109	124	31k	10mo
About the Journal club category Evidence › Journal club journal club randomised trial estimand Pinned Wiki Our recurring session. One named paper per topic, methods first, conclusions last. Everyone reads before posting. This post is a community wiki: any member at trust level 3 or above can edit it, and every…	+2	6	12k	16mo
Why retatrutide discussion here is more cautious than elsewhere — one year on Compounds › Retatrutide TRIUMPH programme effect size preprint retatrutide Asking directly, because I could not find a straight answer: Why retatrutide discussion here is more cautious than elsewhere — one year on Session topic: PIONEER 6 ( N Engl J Med , 2019). Please read it…	+92	97	3.6k	20h
Why fasting instructions for oral semaglutide are not optional advice — does this still hold? Compounds › Oral incretins orforglipron SOUL trial PIONEER programme randomised trial Solved Asking directly, because I could not find a straight answer: Why fasting instructions for oral semaglutide are not optional advice — does this still hold? Session topic: PIONEER 6 ( N Engl J Med , 2019).…	+98	106	3.1k	10mo